Compare WORX & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WORX | CNSP |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3M | 3.8M |
| IPO Year | N/A | 2019 |
| Metric | WORX | CNSP |
|---|---|---|
| Price | $0.24 | $6.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | ★ 11.5M | 73.0K |
| Earning Date | 11-12-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,784,479.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.18 | $4.93 |
| 52 Week High | $1.84 | $114.00 |
| Indicator | WORX | CNSP |
|---|---|---|
| Relative Strength Index (RSI) | 66.99 | 45.58 |
| Support Level | $0.18 | $5.75 |
| Resistance Level | $0.19 | $7.51 |
| Average True Range (ATR) | 0.02 | 0.72 |
| MACD | 0.01 | 0.09 |
| Stochastic Oscillator | 53.31 | 22.58 |
SCWorx Corp is a provider of data content and services related to the repair, normalization, and interoperability of information for healthcare providers, as well as big data analytics for the healthcare industry. Its software enables a healthcare provider to simplify and organize its data, allows the data to be utilized across multiple internal software applications, and provides the basis for sophisticated data analytics. The company has developed and markets healthcare information technology solutions and associated services to improve healthcare processes and information flow within hospitals and other healthcare facilities.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.